MedPath

Clopidogrel

Generic Name
Clopidogrel
Brand Names
Duoplavin, Plavix, Zyllt, Clopidogrel BGR (previously Zylagren), Clopidogrel TAD, Clopidogrel ratiopharm, Clopidogrel Zentiva (previously Clopidogrel Winthrop), Clopidogrel Krka, Clopidogrel Krka d.d. (previously Zopya), Clopidogrel Teva (hydrogen sulphate), Clopidogrel HCS, Iscover, Grepid, Clopidogrel Taw Pharma (previously Clopidogrel Mylan), Clopidogrel Viatris (previously Clopidogrel Taw Pharma)
Drug Type
Small Molecule
Chemical Formula
C16H16ClNO2S
CAS Number
113665-84-2
Unique Ingredient Identifier
A74586SNO7
Background

Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke. Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease,

It has been shown to be superior to aspirin in reducing cardiovascular outcomes in patients with cardiovascular disease and provides additional benefit to patients with acute coronary syndromes already taking aspirin.

Clopidogrel was granted FDA approval on 17 November 1997.

Indication

1.用于新近心肌梗死、新近脑卒中或确诊的周围动脉病变患者,可减少新的缺血性脑卒中、心肌梗死和死亡等心脑血管事件的符合终点;

2.用于急性冠状动脉综合征(不稳定心绞痛和非ST段抬高心肌梗死)患者;

3.用于冠状动脉支架置入术后预防支架内血栓形成(与阿司匹林联用)。

Associated Conditions
Acute Coronary Syndrome (ACS), Acute Myocardial Infarction (AMI), Cardiovascular Events, Atherothrombotic events

Combining Aspirin With Cilostazol or Clopidogrel in Minor Stroke or TIA

Phase 3
Recruiting
Conditions
Ischemic Stroke
Interventions
First Posted Date
2024-09-11
Last Posted Date
2024-09-11
Lead Sponsor
Kafrelsheikh University
Target Recruit Count
870
Registration Number
NCT06591299
Locations
🇪🇬

Kafr Elsheikh University Hospital, Kafr Ash Shaykh, Egypt

Combining Aspirin With Ticagrelor or Clopidogrel in Large-vessel Minor Stroke or TIA

Phase 3
Recruiting
Conditions
Ischemic Stroke
Interventions
First Posted Date
2024-09-11
Last Posted Date
2024-09-11
Lead Sponsor
Kafrelsheikh University
Target Recruit Count
900
Registration Number
NCT06591338
Locations
🇪🇬

Kafr Elsheikh University Hospital, Kafr Ash Shaykh, Egypt

Combining Aspirin With Ticagrelor or Clopidogrel in Minor Stroke or TIA

Phase 3
Recruiting
Conditions
Ischemic Stroke
Interventions
First Posted Date
2024-09-11
Last Posted Date
2024-09-11
Lead Sponsor
Kafrelsheikh University
Target Recruit Count
900
Registration Number
NCT06591312
Locations
🇪🇬

Kafr Elsheikh University Hospital, Kafr Ash Shaykh, Egypt

Combining Aspirin With Cilostazol or Clopidogrel in Large-vessel Minor Stroke or TIA

Phase 3
Recruiting
Conditions
Ischemic Stroke
Interventions
First Posted Date
2024-09-11
Last Posted Date
2024-09-11
Lead Sponsor
Kafrelsheikh University
Target Recruit Count
870
Registration Number
NCT06591351
Locations
🇪🇬

Kafr Elsheikh University Hospital, Kafr Ash Shaykh, Egypt

Study to Assess Pharmacokinetics, Pharmacodynamics and Safety of Tiprogrel in Healthy Subjects

Phase 1
Completed
Conditions
Acute Coronary Syndrome
Ischemic Stroke
Interventions
First Posted Date
2024-09-05
Last Posted Date
2025-01-06
Lead Sponsor
Tianjin Institute of Pharmaceutical Research Co., Ltd
Target Recruit Count
14
Registration Number
NCT06584812
Locations
🇨🇳

Beijing Tiantan Hosptial, Capital Medical University, Beijing, China

Efficacy and Safety Study of Vicagrel in Patients With Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)

Phase 3
Recruiting
Conditions
Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)
Interventions
First Posted Date
2024-08-29
Last Posted Date
2024-10-01
Lead Sponsor
Jiangsu vcare pharmaceutical technology co., LTD
Target Recruit Count
1000
Registration Number
NCT06577519
Locations
🇨🇳

General Hospital of Northern Theater Command of Chinese PLA, Shenyang, Liaoning, China

Cilostazol and Aspirin in Stroke and TIA

Phase 4
Completed
Conditions
TIA
Ischemic Stroke
Interventions
First Posted Date
2024-07-26
Last Posted Date
2024-08-06
Lead Sponsor
Incheon St.Mary's Hospital
Target Recruit Count
378
Registration Number
NCT06522113
Locations
🇰🇷

The Catholic university of korea, Incheon St. Mary's hospital, Incheon, Korea, Republic of

Evaluation of Platelet Aggregability in Patients With Previous Acute Myocardial Infarction or Concomitant Lower Extremity Peripheral Artery Disease

Active, not recruiting
Conditions
Coronary Artery Disease
Peripheral Arterial Disease
Interventions
First Posted Date
2024-06-12
Last Posted Date
2024-06-12
Lead Sponsor
University of Sao Paulo
Target Recruit Count
100
Registration Number
NCT06454045
Locations
🇧🇷

Heart Institute (InCor) / University of São Paulo, São Paulo, Sao Paulo, Brazil

The Nordic Aortic Valve Intervention Trial 4 (NOTION-4)

Not Applicable
Active, not recruiting
Conditions
Heart Diseases
Cardiovascular Diseases
Aortic Valve Stenosis
Heart Valve Diseases
Valve Disease, Aortic
Interventions
First Posted Date
2024-06-10
Last Posted Date
2025-04-06
Lead Sponsor
Rigshospitalet, Denmark
Target Recruit Count
352
Registration Number
NCT06449469
Locations
🇩🇰

Aarhus University Hospital, Skejby, Aarhus, Denmark

🇩🇰

Rigshospitalet, Copenhagen, Denmark

Clopidogrel Versus Cilostazol on Vessels

Phase 4
Recruiting
Conditions
Type 2 Diabetes
Atherosclerosis
Interventions
First Posted Date
2024-05-07
Last Posted Date
2024-05-07
Lead Sponsor
Seoul National University Bundang Hospital
Target Recruit Count
120
Registration Number
NCT06402747
Locations
🇰🇷

Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath